Macular Degeneration Treatment and Research

Marco A. Zarbin, MD, PhD, Chair of Services and Director

(973) 972-2065

The Center for Macular Degeneration Treatment and Research provides state-of-the-art treatment for Age-Related Macular Degeneration (AMD), including the latest FDA approved treatment modalities for neovascular AMD – Macugen (pegaptanib sodium injection) and photodynamic (Visudyne) therapy. Experimental drugs and operations (in the context of Institutional Review Board-approved clinical trials) are also available. The Center is involved in a number of research projects and clinical trials including those related to various aspects of photoreceptor and retinal pigment epithelium transplantation.

Staff
Monique S. Roy, MD
Neelakshi Bhagat, MD